other material
confidence high
sentiment positive
materiality 0.78
Zenas BioPharma announces Phase 2 MoonStone trial of obexelimab meets primary endpoint with 95% lesion reduction
Zenas BioPharma, Inc.
- Obexelimab showed 95% relative reduction in new GdE T1 lesions vs placebo (p=0.0009) at weeks 8 and 12.
- Adjusted mean new GdE T1 lesions per scan: 0.01 (obexelimab) vs 0.23 (placebo).
- Safety consistent with prior trials; most common were mild injection site reactions.
- Expects 24-week MoonStone data in Q1 2026; Phase 3 INDIGO (IgG4-RD) topline around year-end 2025.
- Orelabrutinib Phase 3 in PPMS ongoing; SPMS Phase 3 to initiate Q1 2026.